Published in Heart Disease Weekly, August 31st, 2003
Researchers at the University of Washington were the first to discover Chlamydia pneumoniae, the organism linked by researchers from around the globe to atherosclerotic plaques. The organism is theorized by many to cause or exacerbate chronic inflammatory diseases such as atherosclerosis. Rifalazil, ActivBiotics lead compound, is believed by the company to be the most potent antichlamydial compound in clinical testing, and if...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.